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PELVIC FLOOR DISORDERS AND OVERACTIVE BLADDER: ORIGINAL ARTICLE
Characterisation of urinary monocyte chemoattractant protein 1: Potential
biomarker for patients with overactive bladder
Bilal Farhana, Huiyi Changa, Ahmed Ahmeda,b, Frank Zaldivaira and Gamal Ghoniema
aDepartment of Urology, University of California, Irvine, CA, USA; bDepartment of Urology, Aswan University, Aswan, Egypt
ABSTRACT
Objective: To investigate urinary monocyte chemoattractant protein 1 (MCP-1) as a potential
marker for idiopathic overactive bladder (OAB). This is a quantitative measurement of urinary
MCP-1 to establish baseline normal values that could help in future index studies. Normalised
urinary MCP-1 levels are measured in female patients with OAB and aged-matched controls.
Severity of OAB symptoms is correlated to normalised urinary MCP-1 levels.
Patients and methods: Urinary MCP-1 levels were measured in 29 female patients with OAB
and 10 normal female controls. The patients with OAB were either newly diagnosed or oﬀ any
OAB oral therapy for at least 2 weeks. OAB symptoms were assessed using validated OAB
questionnaires. Urinary MCP-1 levels were measured using enzyme-linked immunosorbent
assay and normalised by urinary creatinine (Cr) levels.
Results: The baseline urinary MCP-1 levels in female patients with OAB were signiﬁcantly
higher than those of the controls, at a mean of 210.25 vs 48.02 pg/mg Cr (P < 0.001). Patients
who had severe OAB bother symptoms had higher levels of urinary MCP-1 (r = 0.03), also
patients with OAB-wet had higher levels of urinary MCP-1, at a mean (SEM) of 209.25 (30.5) vs
OAB-dry 185.25 (10) pg/mg Cr (P < 0.001).
Conclusion: Urinary MCP-1 levels were higher in female patients with idiopathic OAB. The close
association of urinary MCP-1 and OAB bother severity symptoms and OAB-wet suggest that
inﬂammation plays a major role in the pathophysiological mechanisms underlying the sensitisa-
tion of bladder aﬀerent nerves. Establishing urinary MCP-1 levels in patients with OAB hopefully
will help future studies to conﬁrm the correlation as a baseline and changes with treatments.
Abbreviations: BMI: body mass index; Cr: creatinine; MCP-1: monocyte chemoattractant protein
1; OAB: overactive bladder; OAB-q: Overactive Bladder Questionnaire; PPBC: Patient Perception of
Bladder Condition; UI: urinary incontinence
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Introduction
Overactive bladder (OAB) is a group of symptoms
condition of urinary urgency, usually with frequency
and nocturia, with or without urgency urinary incon-
tinence (UI) [1]. Although the aetiology of OAB is
currently still being researched, several recent studies
have proposed that bladder urothelial dysfunction,
with overexpression of sensory receptors, abnormal
function of suburothelial interstitial cells, as well as
increased excitability of detrusor muscles could play
a role in the underlying pathophysiology of OAB [2].
Chronic inﬂammation has been found in bladder
biopsies from patients with neurogenic bladder and
idiopathic OAB [3]. Most recent studies of urinary
chemokines in patients with OAB have shown ele-
vated monocyte chemotactic protein 1 (MCP-1) and
inﬂammatory proteins compared with controls, sug-
gesting that chronic inﬂammation is a key feature in
OAB [4–6]. Many studies have shown that urinary
MCP-1 is expressed in a variety of diﬀerent inﬂamma-
tion and chronic pain conditions [6].
Chemokines are classiﬁed into four subfamilies, i.e.
CXC, CC, CX3C and XC. MCP-1/CCL2 is a member of
the C-C chemokine family, and a potent chemotactic
factor for monocytes. MCP-1 is produced by a variety
of cell types, either constitutively or after induction by
oxidative stress, cytokines, or growth factors [7].
In the present pilot study, we investigated urinary
MCP-1 levels in women with OAB symptoms with
respect to OAB subtypes and severity of symptoms.
Patients and methods
After Institutional Review Board approval, adult
women, diagnosed with OAB, and age-matched healthy
volunteers without LUTS were recruited between
October 2014 and March 2018. All participants signed
an informed consent. All patients with OAB symptoms
underwent history, physical examination, and urine ana-
lysis. Additional tests were done when appropriate, such
as urine culture, uroﬂowmetry, and bladder scan for resi-
dual urine. The newly diagnosed patients with OAB were
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veriﬁed by 3-day voiding diary and only patients with
a daily frequency of >8 episodes of urgency/day (OAB-
dry) or urgency UI ≥1 episode/day (OAB-wet) were diag-
nosed as having OAB. Patients that had already been
diagnosed with OAB had to have stopped taking OAB
medications for at least 2 weeks prior to enrolment.
Patients with neurogenic bladder, BOO, urinary stones,
tumours or UTI at the recruitment were excluded.
Additionally, females with urogenital atrophy, severe
stress UI, vaginitis or active genital disease, positive bac-
terial culture or a post-void residual urine volume of
>150 mL were excluded. Patients were also excluded if
they had any other condition that, in the opinion of the
investigator, made them unsuitable for inclusion. Age-
matched healthy volunteers (controls) were recruited
from hospital staﬀ and had no signiﬁcant LUTS or pain
(AUA Symptom Index <7), no previous diagnosis of OAB,
and no evidence of infection based on a negative nitrite
dipstick test and symptoms. Mid-stream urine samples
were collected at the time of enrolment as a baseline and
centrifuged at 3000 g for 10 min at 4°C to collect the
supernatant, and 1.5 mL aliquots were preserved at – 80°
C. Concurrently, 3 mL urine was taken to measure the
urinary creatinine (Cr), in order to normalise the urinary
MCP-1with the urinary Cr level. No speciﬁc dietary restric-
tions during urine collection were applied.
Urinary MCP-1 levels were measured using R & D
Systems Biotech ELISA Kit (Cat# DCP00; R & D Systems,
Minneapolis, MN, USA). This kit is validated to perform
well in multiple human matrices. The CCL/MCP-1 kit is
intended to determine the quantitative levels of CCL2/
MCP-1 in human urine by an enzyme immunoassay. This
test is a 3.5–4.5 h solid-phase ELISA designed to measure
MCP-1 in cell culture, serum, plasma, and urine. All
reagents were prepared as speciﬁed by the manufac-
turer’s instructions, which includes well washing of the
samples followed by incubation for 30 min at room
temperature by addition of 200 μL substrate into each
well. Finally, a stop solution was added to the wells and
then optical density of each well was assessed using
a microplate reader set at 450 nm. All measurements
were performed in duplicate and the average was used
to subtract from the zero standard optical density. The
total urinary MCP-1 levels were further normalised by the
concentration of urinary Cr. The levels of urinary MCP-1
were expressed as picogrammes (pg) per milligramme
(mg) of Cr for both the controls and patients with OAB.
All data are presented asmeans (standard error of the
mean, SEM). Statistical diﬀerences in mean levels of
normalised urinary MCP-1 in patients with OAB, and
controls, OAB-wet, OAB-dry, as well as age and body
mass index (BMI) were compared using one-way ANOVA
and paired t-tests between subgroups of two means at
their baselines. Pearson’s correlation was used for ana-
lysing the association between normalised urinary MCP-
1 levels and the OAB symptoms bother severity using
the Overactive Bladder Questionnaire (OAB-q) and
Patient Perception of Bladder Condition (PPBC) ques-
tionnaire. All statistical analyses were performed using
the IBM Statistical Package for the Social Sciences
(SPSS®) version 20.0 (SPSS Inc., IBM Corp., Armonk, NY,
USA). A P < 0.05 was considered statistically signiﬁcant.
Results
In all, 29 women with OAB (18 women with OAB-wet, 11
with OAB-dry) and 10 controls were enrolled. The mean
(SEM) age was 60.45 (9) years for the OAB group and 55.2
(12) years for the control group (P= 0.153). Therewas also
no signiﬁcant diﬀerence in the mean age between
women with OAB-dry and OAB-wet (P = 0.223), as well
as compared to the controls (P = 0.236). The baseline
urinary MCP-1 levels for female patients with OAB were
signiﬁcantly higher than those in controls, at a mean of
210.25 vs 48.02 pg/mg Cr (P < 0.001). Additionally, the
normalised urinary MCP-1 levels were signiﬁcantly high-
est in patients with OAB-wet (Table 1). There was no
signiﬁcant diﬀerence in the mean BMI between patients
with OAB-dry and OAB-wet (P = 0.214).
Using Pearson’s correlation, normalised urinary
MCP-1 levels signiﬁcantly correlated with the severity
OAB symptoms on the OAB-q (Figure 1; r = 0.03,
P = 0.003).
Discussion
Much evidence suggests that inﬂammatory processes
are involved in OAB pathogenesis. Ghoniem et al. [8]
proposed the hypothesis of local inﬂammation as
a cause and to play a central role in the aetiology of
OAB. Previous studies have shown that increased urin-
ary levels of MCP-1 are evidence of bladder inﬂamma-
tion [9]. In the present pilot study, we investigated
urinary MCP-1/Cr levels in patients with OAB using
a quantitative method (Quantikine® Human MCP-1
Immunoassay, ELISA designed) and compared it to
healthy age-matched volunteers (controls). The pre-
sent results provide evidence that women with OAB
have higher levels of urinary MCP-1, especially in
those with OAB-wet, suggesting that chronic inﬂam-
mation results in greater expression of urinary MCP-1;
whilst in contrast OAB-dry could be a mixture of
urothelial dysfunction and increased bladder sensa-
tion such as detrusor overactivity. This appears to
indicate that MCP-1 could be a possible marker to
Table 1. Patients with OAB and control subjects, OAB-wet,
OAB-dry, age, and BMI.
OAB (n = 29)
Variable, mean
(SEM)
Control
(n = 10)
OAB-wet
(n = 18)
OAB-dry
(n = 11) P (ANOVA)
Urinary MCP-1,
pg/mg Cr
48.02 (9) 209.25 (30.5) 185.25 (10) 0.001
Age, years 55.2 (12) 58.4 (8) 62.5 (10) 0.236
BMI, kg/m2 28.3 (0.2) 30.6 (2.7) 29.4 (2) 0.626
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diﬀerentiate between OAB subtypes. The other reason
could be the result of higher degree of inﬂammation
and higher percentage of detrusor overactivity.
There were close correlations between the urinary
MCP-1/Cr levels and the severity of OAB symptoms.
This ﬁnding is the main strength of our present study,
suggesting the ability to predict the severity of symp-
toms with levels of urinary MCP-1/Cr. The mechanism
through which urinary levels of MCP-1 increase in
patients with OAB is not yet well establish. Stretching
of the bladder smooth muscle cells increases the
expression of mRNA leading to increased expression
and secretion of urinary cytokines [10]. Further investi-
gations and studies are needed to conﬁrm the present
results, as well as the precise mechanisms involved.
A limitation of the present pilot study was the small
cohort of controls and patients with OAB. A larger sam-
ple size will enable a more detailed study with follow-up
of the response of urinary MCP-1 to OAB treatments.
Overall, our present ﬁndings may serve as a basis
to study the pathogenesis of OAB in the context of
chronic systemic inﬂammation. The level of urinary
MCP-1 might serve as a potential tool for studying
the progression, severity, and to assess the therapeu-
tic eﬀects of treatment, allowing a better understand-
ing of the pathophysiology of the OAB syndrome.
In conclusion, urinary MCP-1 was signiﬁcantly
higher in women with OAB-dry and OAB-wet. Higher
urinary MCP-1 in OAB-wet could be related to a local
inﬂammatory disorder, which is unrelated to obesity
and ageing. This ﬁnding may help to understand the
pathogenesis of OAB in the context of chronic inﬂam-
mation, which might give the light at the end of the
tunnel for treatment of patients with OAB syndrome.
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Figure 1. Relationship between mean urinary MCP-1/Cr levels and OAB symptoms using Spearman correlation coeﬃcient.
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